PHARMACEUTICAL INNOVATIONS

Pipeline

EDE Pharmaceuticals is structured to act as a solution engine for pharmaceutical companies seeking precision-matched assets for specific biological targets or disease programs.
Our diversified pipeline of more than 1,000 candidates spans multiple therapeutic areas and is prepared to progress rapidly into advanced preclinical and clinical development.

EXPLORE OUR BREAKTHOUGH CANDIDATES
Oncology
Asset ID Added Value Indication Market Size STAGE
Hit-To-Lead Lead Optimization In Vitro Poc In Vivo Poc IND Submission Clinical Development
EDE-MCC-211 First-in-class approach targeting viral-driven tumors; high unmet need Merkel Cell Carcinoma $10.9B
Target ID: DLL3
 
 
 
 
 
EDE-TNB-618 Designed to overcome resistance; strong positioning in large TNBC market Triple-Negative Breast Cancer $20B
Target ID: HER3
 
 
 
 
 
EDE-BLA-378 Cleaner safety profile vs current FGFR inhibitors; reduced toxicity risk Bladder Cancer (FGFR3) $14B
Target ID: FGFR3
 
 
 
 
 
EDE-ALX-204 Overcomes resistance mutations; potential best-in-class profile Lung Cancer (ALK+) $50B
Target ID: ALK
 
 
 
 
 
EDE-GKR-101 Brain-penetrant KRAS inhibitor; key differentiation vs current therapies Lung Cancer (KRAS G12C) $11.4B
Target ID: ALK
 
 
 
 
 
EDE-PED-340 Enables CAR-T eligibility; orphan indication with fast-track potential Pediatric ALL (Leukemia) $9.1B
Target ID: IL7R
 
 
 
 
 
Metabolic Disease
Asset ID Added Value Indication Market Size STAGE
Hit-To-Lead Lead Optimization In Vitro Poc In Vivo Poc IND Submission Clinical Development
EDE-ORA-615 Oral alternative to injectables; improves patient compliance Obesity (Oral GLP-1) $95B
Target ID: GLP1R
 
 
 
 
 
EDE-OBE-771 Dual mechanism with lean-mass preservation; differentiated vs GLP-1s Obesity + Type 2 Diabetes $167B
Target ID: GCGR/GIPR
 
 
 
 
 
Oncology
Asset ID Indication Market Size STAGE
Hit To Lead Lead Opt.. In Vitro Poc
EDE-MCC-211 Merkel Cell Carcinoma $10.9B
Target ID: DLL3
 
 
EDE-TNB-618 Triple-Negative Breast Cancer $20B
Target ID: HER3
 
 
EDE-BLA-378 Bladder Cancer (FGFR3) $14B
Target ID: FGFR3
 
 
EDE-ALX-204 Lung Cancer (ALK+) $50B
Target ID: ALK
 
 
EDE-GKR-101 Lung Cancer (KRAS G12C) $11.4B
Target ID: KRAS
 
 
EDE-PED-340 Pediatric ALL (Leukemia) $9.1B
Target ID: IL7R
 
 
Metabolic Disease
Asset ID Indication Market Size STAGE
Hit To Lead Lead Opt.. In Vitro Poc
EDE-ORA-615 Obesity (Oral GLP-1) $95B
Target ID: GLP1R
 
 
EDE-OBE-771 Obesity + Type 2 Diabetes $167B
Target ID: GCGR/GIPR
 
 
Oncology
Indication Market Size STAGE
In Vitro Poc
Merkel Cell Carcinoma $10.9B
DLL3
Triple-Negative Breast Cancer $20B
HER3
Bladder Cancer (FGFR3) $14B
FGFR3
Lung Cancer (ALK+) $50B
ALK
Lung Cancer (KRAS G12C) $11.4B
KRAS
Pediatric ALL (Leukemia) $9.1B
IL7R
Metabolic Disease
Indication Market Size STAGE
In Vitro Poc
Obesity (Oral GLP-1) $95B
GLP1R
Obesity + Type 2 Diabetes $167B
GCGR/GIPR

Global Footprint

EDE Pharmaceuticals operates across multiple strategic scientific and commercial regions globally.
Global Headquarters in Dubai, UAE. Al Fattan Currency House, Tower 2,Office 1802-1803, Financial Center.

Other ways to Connect

Prefer to reach us directly? Here's how to get in touch.

Email

Email us for general enquiries
and media requests
or send us email at partnering@ede.ae
‍
send email

Telephone

Monday-Friday,
9am-6pm Gulf Standard Time
(+971) 4 254 33139
‍
call us

Post

Headquarters:
Al Fattan Currency House, Tower 2,
Office 1802-1803,
Dubai International Financial Center, UAE
find us
Al Fattan Currency House, Tower 2, Office 1802 -1803, Dubai International Financial Center, UAE
EMAIL US
CALL US
COMPANY
Home
ABOUT
TECHNOLOGY
NEWS
PARTNERS
CAREERS
CONTACT
© 2025 EDE
TERMS
PRIVACY
Privacy Policy Cookie Policy